---
document_datetime: 2025-12-29 11:03:50
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/lydisilka.html
document_name: lydisilka.html
version: success
processing_time: 0.1051275
conversion_datetime: 2025-12-29 23:31:00.683448
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Lydisilka

[RSS](/en/individual-human-medicine.xml/67444)

##### Authorised

This medicine is authorised for use in the European Union

estetrol / drospirenone Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Lydisilka](#news-on)
- [More information on Lydisilka](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Lydisilka is a combined hormonal contraceptive. It contains the active substances drospirenone and estetrol monohydrate.

Expand section

Collapse section

## How is Lydisilka used?

Lydisilka can only be obtained with a prescription. It comes in blisters containing 28 tablets (24 'active' tablets and 4 'inactive' tablets that do not contain the active substances).

Tablets are taken by mouth in sequence, starting on the first day of the menstrual cycle with the active tablets, followed by the 4 inactive tablets. Each subsequent pack is started the day after finishing the previous pack, for as long as contraception is required. For more information about using Lydisilka, see the package leaflet or contact your doctor, pharmacist or prescriber.

## How does Lydisilka work?

Lydisilka is a combined contraceptive pill that contains two active substances, drospirenone (a progestogen) and estetrol (an oestrogen). Estetrol is a synthetic version of an oestrogen that is naturally present during pregnancy, and drospirenone is a hormone with similar effects to the progesterone produced during the menstrual cycle. Both these substances change the body's hormonal balance to prevent ovulation.

## What benefits of Lydisilka have been shown in studies?

Lydisilka was found to be effective at preventing unwanted pregnancies in 2 main studies involving a total of around 3,400 women.

The main measure of effectiveness was the number of unwanted pregnancies in 100 women-years (corresponding to 100 women taking contraception for one year). This measure is known as the Pearl Index, and a lower Pearl Index represents a lower chance of getting pregnant.

In a first study conducted in 1,553 women between the ages of 18 and 50, the Pearl Index was 0.44 in the group aged 18 to 35 and 0.38 in the whole group. This was considered a sufficiently low value for an oral contraceptive.

In a second study, conducted in 1,864 women aged 16 to 50 years old, where more pregnancies were reported, the Pearl Index was 2.42 in women aged 16 to 35 and 2.30 in the group aged 16 to 50.

## What are the risks associated with Lydisilka?

The most common side effects with Lydisilka (which may affect up to 1 in 10 people) are irregular bleeding between periods (metrorrhagia), headache, acne, vaginal bleeding and painful periods (dysmenorrhoea). For the full list of side effects of Lydisilka, see the package leaflet.

Lydisilka should not be used by women with a history of blood clots in the veins or arteries, or by women with risk factors for blood clots. It should also not be used by women who have experienced severe liver and kidney problems, liver tumours, hormone-dependent cancers, or abnormal bleeding from the genital area of unknown cause. For the full list of restrictions, see the package leaflet.

## Why is Lydisilka authorised in the EU?

Overall, Lydisilka was considered effective at preventing unwanted pregnancies. In terms of safety, the side effects of Lydisilka are similar to those of other combined hormonal contraceptives and are in line with what would be expected with an oestrogen and a progestogen pill. The European Medicines Agency therefore decided that Lydisilka's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Lydisilka?

The company that markets Lydisilka will provide a checklist for healthcare professionals and an information card for women to help manage the risk of thromboembolic events.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Lydisilka have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Lydisilka are continuously monitored. Side effects reported with Lydisilka are carefully evaluated and any necessary action taken to protect patients.

## Other information about Lydisilka

Lydisilka received a marketing authorisation valid throughout the EU on 19/05/2021.

Lydisilka : EPAR - Medicine overview

Reference Number: EMA/245189/2021

English (EN) (104.77 KB - PDF)

**First published:** 02/06/2021

[View](/en/documents/overview/lydisilka-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-699)

български (BG) (130.96 KB - PDF)

**First published:**

02/06/2021

[View](/bg/documents/overview/lydisilka-epar-medicine-overview_bg.pdf)

español (ES) (106.52 KB - PDF)

**First published:**

02/06/2021

[View](/es/documents/overview/lydisilka-epar-medicine-overview_es.pdf)

čeština (CS) (126.37 KB - PDF)

**First published:**

02/06/2021

[View](/cs/documents/overview/lydisilka-epar-medicine-overview_cs.pdf)

dansk (DA) (104.98 KB - PDF)

**First published:**

02/06/2021

[View](/da/documents/overview/lydisilka-epar-medicine-overview_da.pdf)

Deutsch (DE) (109.52 KB - PDF)

**First published:**

02/06/2021

[View](/de/documents/overview/lydisilka-epar-medicine-overview_de.pdf)

eesti keel (ET) (103.74 KB - PDF)

**First published:**

02/06/2021

[View](/et/documents/overview/lydisilka-epar-medicine-overview_et.pdf)

ελληνικά (EL) (130.97 KB - PDF)

**First published:**

02/06/2021

[View](/el/documents/overview/lydisilka-epar-medicine-overview_el.pdf)

français (FR) (108.06 KB - PDF)

**First published:**

02/06/2021

[View](/fr/documents/overview/lydisilka-epar-medicine-overview_fr.pdf)

hrvatski (HR) (126.46 KB - PDF)

**First published:**

02/06/2021

[View](/hr/documents/overview/lydisilka-epar-medicine-overview_hr.pdf)

italiano (IT) (104.84 KB - PDF)

**First published:**

02/06/2021

[View](/it/documents/overview/lydisilka-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (126.17 KB - PDF)

**First published:**

02/06/2021

[View](/lv/documents/overview/lydisilka-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (126.36 KB - PDF)

**First published:**

02/06/2021

[View](/lt/documents/overview/lydisilka-epar-medicine-overview_lt.pdf)

magyar (HU) (126.78 KB - PDF)

**First published:**

02/06/2021

[View](/hu/documents/overview/lydisilka-epar-medicine-overview_hu.pdf)

Malti (MT) (151.84 KB - PDF)

**First published:**

02/06/2021

[View](/mt/documents/overview/lydisilka-epar-medicine-overview_mt.pdf)

Nederlands (NL) (106.33 KB - PDF)

**First published:**

02/06/2021

[View](/nl/documents/overview/lydisilka-epar-medicine-overview_nl.pdf)

polski (PL) (129.86 KB - PDF)

**First published:**

02/06/2021

[View](/pl/documents/overview/lydisilka-epar-medicine-overview_pl.pdf)

português (PT) (107.65 KB - PDF)

**First published:**

02/06/2021

[View](/pt/documents/overview/lydisilka-epar-medicine-overview_pt.pdf)

română (RO) (125.79 KB - PDF)

**First published:**

02/06/2021

[View](/ro/documents/overview/lydisilka-epar-medicine-overview_ro.pdf)

slovenčina (SK) (127.82 KB - PDF)

**First published:**

02/06/2021

[View](/sk/documents/overview/lydisilka-epar-medicine-overview_sk.pdf)

slovenščina (SL) (125.15 KB - PDF)

**First published:**

02/06/2021

[View](/sl/documents/overview/lydisilka-epar-medicine-overview_sl.pdf)

Suomi (FI) (103.2 KB - PDF)

**First published:**

02/06/2021

[View](/fi/documents/overview/lydisilka-epar-medicine-overview_fi.pdf)

svenska (SV) (104.73 KB - PDF)

**First published:**

02/06/2021

[View](/sv/documents/overview/lydisilka-epar-medicine-overview_sv.pdf)

Lydisilka : EPAR - Risk-management-plan summary

English (EN) (174.05 KB - PDF)

**First published:** 02/06/2021

[View](/en/documents/rmp-summary/lydisilka-epar-risk-management-plan-summary_en.pdf)

## Product information

Lydisilka : EPAR - Product information

English (EN) (592.84 KB - PDF)

**First published:** 02/06/2021

**Last updated:** 28/03/2025

[View](/en/documents/product-information/lydisilka-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-77)

български (BG) (1.04 MB - PDF)

**First published:**

02/06/2021

**Last updated:**

28/03/2025

[View](/bg/documents/product-information/lydisilka-epar-product-information_bg.pdf)

español (ES) (850.93 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

28/03/2025

[View](/es/documents/product-information/lydisilka-epar-product-information_es.pdf)

čeština (CS) (892.73 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

28/03/2025

[View](/cs/documents/product-information/lydisilka-epar-product-information_cs.pdf)

dansk (DA) (885.27 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

28/03/2025

[View](/da/documents/product-information/lydisilka-epar-product-information_da.pdf)

Deutsch (DE) (954.23 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

28/03/2025

[View](/de/documents/product-information/lydisilka-epar-product-information_de.pdf)

eesti keel (ET) (786.82 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

28/03/2025

[View](/et/documents/product-information/lydisilka-epar-product-information_et.pdf)

ελληνικά (EL) (1.08 MB - PDF)

**First published:**

02/06/2021

**Last updated:**

28/03/2025

[View](/el/documents/product-information/lydisilka-epar-product-information_el.pdf)

français (FR) (920.25 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

28/03/2025

[View](/fr/documents/product-information/lydisilka-epar-product-information_fr.pdf)

hrvatski (HR) (873.74 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

28/03/2025

[View](/hr/documents/product-information/lydisilka-epar-product-information_hr.pdf)

íslenska (IS) (834.21 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

28/03/2025

[View](/is/documents/product-information/lydisilka-epar-product-information_is.pdf)

italiano (IT) (897.29 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

28/03/2025

[View](/it/documents/product-information/lydisilka-epar-product-information_it.pdf)

latviešu valoda (LV) (1015.48 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

28/03/2025

[View](/lv/documents/product-information/lydisilka-epar-product-information_lv.pdf)

lietuvių kalba (LT) (852.89 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

28/03/2025

[View](/lt/documents/product-information/lydisilka-epar-product-information_lt.pdf)

magyar (HU) (915.96 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

28/03/2025

[View](/hu/documents/product-information/lydisilka-epar-product-information_hu.pdf)

Malti (MT) (1.05 MB - PDF)

**First published:**

02/06/2021

**Last updated:**

28/03/2025

[View](/mt/documents/product-information/lydisilka-epar-product-information_mt.pdf)

Nederlands (NL) (915.81 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

28/03/2025

[View](/nl/documents/product-information/lydisilka-epar-product-information_nl.pdf)

norsk (NO) (872.73 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

28/03/2025

[View](/no/documents/product-information/lydisilka-epar-product-information_no.pdf)

polski (PL) (998.78 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

28/03/2025

[View](/pl/documents/product-information/lydisilka-epar-product-information_pl.pdf)

português (PT) (835.23 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

28/03/2025

[View](/pt/documents/product-information/lydisilka-epar-product-information_pt.pdf)

română (RO) (1.03 MB - PDF)

**First published:**

02/06/2021

**Last updated:**

17/09/2025

[View](/ro/documents/product-information/lydisilka-epar-product-information_ro.pdf)

slovenčina (SK) (895.62 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

28/03/2025

[View](/sk/documents/product-information/lydisilka-epar-product-information_sk.pdf)

slovenščina (SL) (842.31 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

28/03/2025

[View](/sl/documents/product-information/lydisilka-epar-product-information_sl.pdf)

Suomi (FI) (889.47 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

28/03/2025

[View](/fi/documents/product-information/lydisilka-epar-product-information_fi.pdf)

svenska (SV) (865.71 KB - PDF)

**First published:**

02/06/2021

**Last updated:**

28/03/2025

[View](/sv/documents/product-information/lydisilka-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0026 26/02/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Lydisilka : EPAR - All authorised presentations

English (EN) (44.67 KB - PDF)

**First published:** 02/06/2021

[View](/en/documents/all-authorised-presentations/lydisilka-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-630)

български (BG) (61.18 KB - PDF)

**First published:**

02/06/2021

[View](/bg/documents/all-authorised-presentations/lydisilka-epar-all-authorised-presentations_bg.pdf)

español (ES) (44.93 KB - PDF)

**First published:**

02/06/2021

[View](/es/documents/all-authorised-presentations/lydisilka-epar-all-authorised-presentations_es.pdf)

čeština (CS) (44.01 KB - PDF)

**First published:**

02/06/2021

[View](/cs/documents/all-authorised-presentations/lydisilka-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (45.36 KB - PDF)

**First published:**

02/06/2021

[View](/da/documents/all-authorised-presentations/lydisilka-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (46.09 KB - PDF)

**First published:**

02/06/2021

[View](/de/documents/all-authorised-presentations/lydisilka-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (45.15 KB - PDF)

**First published:**

02/06/2021

[View](/et/documents/all-authorised-presentations/lydisilka-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (60.96 KB - PDF)

**First published:**

02/06/2021

[View](/el/documents/all-authorised-presentations/lydisilka-epar-all-authorised-presentations_el.pdf)

français (FR) (45.03 KB - PDF)

**First published:**

02/06/2021

[View](/fr/documents/all-authorised-presentations/lydisilka-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (61.43 KB - PDF)

**First published:**

02/06/2021

[View](/hr/documents/all-authorised-presentations/lydisilka-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (45.06 KB - PDF)

**First published:**

02/06/2021

[View](/is/documents/all-authorised-presentations/lydisilka-epar-all-authorised-presentations_is.pdf)

italiano (IT) (44.73 KB - PDF)

**First published:**

02/06/2021

[View](/it/documents/all-authorised-presentations/lydisilka-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (60.38 KB - PDF)

**First published:**

02/06/2021

[View](/lv/documents/all-authorised-presentations/lydisilka-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (63.47 KB - PDF)

**First published:**

02/06/2021

[View](/lt/documents/all-authorised-presentations/lydisilka-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (61.12 KB - PDF)

**First published:**

02/06/2021

[View](/hu/documents/all-authorised-presentations/lydisilka-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (61.92 KB - PDF)

**First published:**

02/06/2021

[View](/mt/documents/all-authorised-presentations/lydisilka-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (44.51 KB - PDF)

**First published:**

02/06/2021

[View](/nl/documents/all-authorised-presentations/lydisilka-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (44.83 KB - PDF)

**First published:**

02/06/2021

[View](/no/documents/all-authorised-presentations/lydisilka-epar-all-authorised-presentations_no.pdf)

polski (PL) (55 KB - PDF)

**First published:**

02/06/2021

[View](/pl/documents/all-authorised-presentations/lydisilka-epar-all-authorised-presentations_pl.pdf)

português (PT) (44.93 KB - PDF)

**First published:**

02/06/2021

[View](/pt/documents/all-authorised-presentations/lydisilka-epar-all-authorised-presentations_pt.pdf)

română (RO) (50.49 KB - PDF)

**First published:**

02/06/2021

[View](/ro/documents/all-authorised-presentations/lydisilka-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (59.7 KB - PDF)

**First published:**

02/06/2021

[View](/sk/documents/all-authorised-presentations/lydisilka-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (62.5 KB - PDF)

**First published:**

02/06/2021

[View](/sl/documents/all-authorised-presentations/lydisilka-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (44.41 KB - PDF)

**First published:**

02/06/2021

[View](/fi/documents/all-authorised-presentations/lydisilka-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (43.96 KB - PDF)

**First published:**

02/06/2021

[View](/sv/documents/all-authorised-presentations/lydisilka-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Lydisilka Active substance

- estetrol monohydrate
- drospirenone

International non-proprietary name (INN) or common name

- estetrol
- drospirenone

Therapeutic area (MeSH) Contraceptives, Oral Anatomical therapeutic chemical (ATC) code G03

### Pharmacotherapeutic group

Sex hormones and modulators of the genital system

### Therapeutic indication

Oral contraception.

The decision to prescribe Lydisilka should take into consideration the individual woman's current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with Lydisilka compares with other combined hormonal contraceptives (CHCs) (see sections 4.3 and 4.4).

## Authorisation details

EMA product number EMEA/H/C/005382

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Estetra SPRL

Rue Saint-Georges 5

Opinion adopted 25/03/2021 Marketing authorisation issued 19/05/2021 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Lydisilka : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (186.78 KB - PDF)

**First published:** 29/11/2021

**Last updated:** 28/03/2025

[View](/en/documents/procedural-steps-after/lydisilka-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Lydisilka : EPAR - Statement indicating compliance with the agreed completed paediatric investigation plan

Reference Number: EMA/39706/2025

English (EN) (123.26 KB - PDF)

**First published:** 28/03/2025

[View](/en/documents/pip-compliance/lydisilka-epar-statement-indicating-compliance-agreed-completed-paediatric-investigation-plan_en.pdf)

## Initial marketing authorisation documents

Lydisilka : EPAR - Public assessment report

Adopted

Reference Number: EMA/212535/2021

English (EN) (2.65 MB - PDF)

**First published:** 02/06/2021

[View](/en/documents/assessment-report/lydisilka-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Lydisilka

Adopted

Reference Number: EMA/CHMP/156178/2021

English (EN) (119.11 KB - PDF)

**First published:** 26/03/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-lydisilka_en.pdf)

#### News on Lydisilka

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 March 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-march-2021) 26/03/2021

#### More information on Lydisilka

- [EMEA-001332-PIP01-12-M06 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001332-pip01-12-m06)
- [International Active Surveillance Study: Native Estrogen Estetrol (E4) Safety Study (INAS-NEES) - post-authorisation study](https://catalogues.ema.europa.eu/study/49985)

**This page was last updated on** 28/03/2025

## Share this page

[Back to top](#main-content)